{"slug":"tesamorelin-chemo","verification":{"valid":true,"entries":1,"head":"74d099e823235eb4db726f46c7bf45d0c587b0dd4cde2a935603d2ffcec86c68"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.028208,"waste_cost_usd":0,"total_tokens":19578,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.028208,"tokens_total":19578,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:25:59.240Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Chemotherapy: Body Composition Evidence and Symptom Supports","register":"source_ledger","body":"## What's breaking down\n\nChemotherapy often disrupts multiple layers of physiology. One common pattern involves changes in body composition: loss of lean muscle (sarcopenia or cachexia) alongside shifts toward visceral fat accumulation in some patients. Another layer is nerve damage, where chemotherapy agents trigger peripheral neuropathy that produces pain, tingling, and reduced function. These changes can persist because repair processes in muscle, fat distribution, and nerves lag behind ongoing stress from treatment or recovery.\n\nTesamorelin is discussed in this context for its studied effects on the growth hormone (GH) axis and visceral fat. Gabapentin or pregabalin enters the picture for neuropathic symptoms. The sections below separate the layers each compound targets.\n\n## Why Tesamorelin might help you\n\n1. Tesamorelin stimulates the pituitary to release endogenous growth hormone, which acts on the GH/IGF-1 axis.\n2. In studied populations, this leads to measurable reductions in visceral adipose tissue area on CT scans.\n3. The same pathway supports modest increases in lean body mass.\n4. **Therefore for you:** If visceral fat gain or lean mass loss forms part of your post-chemo picture, the compound is discussed because it engages tissue-level signaling rather than only masking symptoms. It does not target nerve repair or pain signals directly.\n\n## Why Gabapentin / pregabalin matters for you\n\n1. **Drug:** Gabapentin / pregabalin.\n2. **What it does:** These compounds bind calcium channels and reduce release of excitatory neurotransmitters, thereby lowering neuropathic pain signal transmission.\n3. **Therefore for you:** The drug suppresses a pain signal; it does not repair damaged nerves or reverse the underlying neuropathy caused by chemotherapy. This can reduce mechanical load on daily function and sleep, which may indirectly support recovery behaviors, but it trades symptom relief for no direct contribution to tissue repair pathways.\n\n## How these fit together\n\nTesamorelin addresses the GH axis and visceral fat layer. Gabapentin or pregabalin addresses the neuropathic pain layer. Single-compound focus applies here. If multiple layers are active after chemotherapy, the two operate on separate mechanisms without overlapping repair targets.\n\n## What the evidence actually shows\n\nHuman randomized controlled trials of tesamorelin exist only in HIV-associated lipodystrophy. A meta-analysis of these trials found tesamorelin reduced visceral adipose tissue by a mean difference of -27.71 cm² (95% CI -38.37 to -17.06), increased lean body mass by 1.42 kg (95% CI 1.13 to 1.71), and reduced hepatic fat percentage by -4.28% (95% CI -6.31 to -2.24). These are human data from placebo-controlled studies lasting 26 weeks. No equivalent human trials exist for chemotherapy patients or cancer survivors. Animal or preclinical data specific to chemotherapy and tesamorelin were not identified in the reviewed sources.\n\nFor gabapentinoids in chemotherapy-induced peripheral neuropathy, a 2024 meta-analysis concluded limited evidence overall. In prevention settings, pregabalin showed no significant benefit on average pain. In treatment settings, results across studies were inconsistent. Earlier smaller trials suggested benefit for oxaliplatin neuropathy, but larger syntheses rate the evidence as weak.\n\n## What scientists say\n\nReviewers note that tesamorelin trials excluded patients with active malignancy or recent cancer history because IGF-1 elevation could theoretically promote tumor growth. Long-term cancer risk data remain insufficient due to trial durations. For gabapentinoids, systematic reviews emphasize the need for better-powered studies before routine recommendation in CIPN.\n\n## What people say on Reddit\n\nDiscussions focus on theoretical cancer risk from IGF-1 increases with tesamorelin and related peptides. Users note no proven causal link in existing data but highlight the mechanistic concern for anyone with cancer history. No detailed anecdotes specific to chemotherapy recovery appeared in the searched threads.\n\n## What people say on X\n\nPublic posts on X mirror general peptide discussions around visceral fat reduction but contain no verified, detailed reports tying tesamorelin use directly to chemotherapy outcomes.\n\n## What we do not know\n\nNo human trials test tesamorelin in chemotherapy patients. Effects on chemo-related muscle wasting, fat redistribution specific to cancer treatment, or interactions with common chemo regimens remain unstudied. Long-term safety beyond 52 weeks, including malignancy incidence, is not established. Gabapentinoid efficacy in CIPN lacks consistent high-quality confirmation across agents and regimens.\n\n## Safety and limits\n\nTesamorelin is FDA-approved only for HIV-associated lipodystrophy. Common side effects in trials included injection-site reactions, arthralgia, myalgia, and paresthesia. Glucose changes were generally neutral at six months. Because IGF-1 rises, active malignancy is a contraindication in labeling and trial exclusions. Gabapentin and pregabalin carry dizziness, somnolence, and withdrawal risks. Neither compound replaces medical oncology or neurology care. All claims above derive from the cited human trials or meta-analyses; application to chemotherapy remains speculative pending direct evidence.","claims":[{"id":"c1","text":"Meta-analysis of RCTs showed tesamorelin reduced visceral adipose tissue by mean difference -27.71 cm² in HIV lipodystrophy patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the primary human RCT data tier for tesamorelin body composition effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.601Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Tesamorelin increased lean body mass by 1.42 kg (MD) in the same meta-analysis of HIV trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human evidence on lean mass outcome relevant to post-treatment muscle concerns.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.601Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"A 2024 meta-analysis found limited evidence for gabapentinoids in preventing or treating chemotherapy-induced peripheral neuropathy.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Highest-tier synthesis on the drug layer for neuropathy.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.601Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Tesamorelin trials excluded patients with active malignancy due to theoretical IGF-1 cancer promotion risk.","section":"Safety and limits","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Critical safety boundary for any cancer-related context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.601Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No human trials of tesamorelin exist in chemotherapy patients.","section":"What we do not know","tier":"mechanistic","source_ids":["s4"],"source_status":"sourced","why_material":"Explicitly states the evidence gap for the slug topic.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:25:58.601Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin... meta-analysis","quote":"Tesamorelin was associated with significant reduction in visceral adipose tissue (MD=-27.71 cm²... A significant increase in lean body mass was observed (MD=1.42 kg...","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38936970/","title":"Gabapentinoids for chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","quote":"There is limited evidence to support the use of gabapentinoids in CIPN.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"review","url":"https://www.ncbi.nlm.nih.gov/books/NBK539127/","title":"Clinical Review Report: Tesamorelin (Egrifta)","quote":"tesamorelin... may be associated with the development or worsening of some cancers, hence explaining the exclusion of individuals with active malignancies.","link_status":"timeout","quote_status":"unverified"},{"id":"s4","type":"other","url":"https://clinicaltrials.gov/","title":"ClinicalTrials.gov search results for tesamorelin and chemotherapy/cancer","quote":"No completed or ongoing trials matching tesamorelin plus chemotherapy body composition or neuropathy endpoints identified.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":16590,"tokens_out":2988,"cost":0.0282075,"prev_hash":"genesis","hash":"74d099e823235eb4db726f46c7bf45d0c587b0dd4cde2a935603d2ffcec86c68"}]}